GLP-1 and the Finance Problem Nobody Talks About

EXECUTIVE SUMMARY

The GLP-1 market doubled in two years. The financial infrastructure did not.

The U.S. medical weight management market grew from approximately $15 billion in 2022 to $33.8 billion in 2024, driven almost entirely by the explosion in demand for GLP-1 receptor agonist therapies — semaglutide, tirzepatide, and their compounded equivalents. Clinic groups expanded from one location to ten. Compounding pharmacies added GLP-1 programs overnight. Telehealth platforms dispensing GLP-1 therapies emerged faster than anyone had anticipated.

What did not keep pace with that growth was the financial infrastructure behind it. Most weight management clinics and compounding pharmacy operators running GLP-1 programs are managing high-cost medication inventory, evolving insurance coverage rules, multi-modality billing, and patient program revenue recognition on accounting systems that were built for a single-location practice or a retail pharmacy — not a scaled, multi-entity healthcare business with a drug at the center that payers have not finished deciding how to cover.

This whitepaper addresses the specific financial management problems that GLP-1 program operators face — and what the financial infrastructure needs to look like to run these programs profitably at scale.

Key Market Indicators

1. $33.8B – U.S. weight management market, 2024
2. 2× – Market growth 2022 to 2024
3. Varies – Insurance coverage by payer and plan
4. 15¢ – Lost per dollar billed on avg. in healthcare

THE FINANCE PROBLEM

Three financial management failures hiding inside a fast-growing GLP-1 program

The financial problems facing GLP-1 program operators are not unique to GLP-1 — they are the classic problems of a healthcare business scaling faster than its systems. What makes GLP-1 different is the combination of high medication cost, unstandardized insurance coverage, and the hybrid clinical-pharmacy operating model that most programs run. Each of those factors amplifies the financial management risk in a way that operators who have not seen it before tend not to anticipate until it shows up in the financials.

Failure 1: Billing for services payers have not standardized

Insurance coverage for GLP-1 medications and obesity medicine services varies significantly by payer and plan — and it continues to evolve. Medicare Part D covers GLP-1s for diabetes but not for weight loss under most plans. Commercial payers have widely divergent formulary positions. Medicaid coverage varies by state. The ICD-10 coding that triggers coverage for one payer triggers a denial for another.

For a clinic billing obesity medicine services across multiple payers without current, payer-specific contract logic in the financial system, denials accumulate in categories that are entirely preventable. The denial rate on GLP-1-related services at clinics without revenue cycle integration routinely runs well above the already-elevated industry average of 11.8%.

The compounding pharmacy dimension:

For compounding pharmacies running GLP-1 programs, most revenue is cash-pay rather than insurance-billed — which eliminates the denial problem but creates a different one: patient payment collection, subscription program management, and high-value prescription fulfillment that needs to be tracked against inventory at the lot level. The financial management requirements are different from a clinical program but equally complex at scale.

Failure 2: High-cost inventory with no real-time visibility

GLP-1 therapies are among the most expensive outpatient medications in common use. Semaglutide and tirzepatide pens carry list prices of $1,000 or more per month. Compounded equivalents are cheaper but still represent significant per-unit cost compared to traditional compounded medications. For a clinic or pharmacy dispensing GLP-1s at volume, medication inventory is a material asset — and losing track of it has direct financial consequences.

Most weight management clinic operators and compounding pharmacies do not have real-time inventory visibility tied to the financial system. Medication stock is tracked in a dispensing system or a spreadsheet. The cost of goods dispensed is recorded monthly based on a reconciliation between the ordering system and the accounting system. Expiration waste, variance between ordered and dispensed, and lot-level traceability for recall readiness are all managed outside the ERP — if they are managed at all.

What happens without inventory integration

1. Cost of goods dispensed is estimated monthly rather than calculated in real time, creating a lag between operational performance and financial reporting
2. Medication waste from expiration or damage is recorded inconsistently, distorting gross margin calculations
3. Lot-level traceability is not maintained in the financial system, creating exposure when a compounded batch requires a recall or withdrawal
4. Carrying costs for high-value inventory are not visible to finance leadership, preventing informed decisions about ordering cadence and storage capacity

What inventory integration in NetSuite provides

1. Real-time COGS posting as medication is dispensed, giving finance an accurate gross margin picture without waiting for month-end reconciliation
2. Lot and expiration tracking within the ERP, with automated alerts when inventory approaches expiration thresholds
3. Variance reporting between ordered and dispensed quantities, surfacing shrinkage or dispensing errors as they occur
4. Carrying cost visibility by SKU and lot, supporting informed decisions about which GLP-1 formulations and dosage forms to stock at what levels

Failure 3: Patient program revenue recognition that does not fit standard billing

Most GLP-1 weight management programs are not structured as simple fee-for-service clinical encounters. They are programs: a monthly membership that includes provider visits, medication management, coaching, and in some cases the medication itself bundled into the program fee. That structure is operationally attractive because it creates recurring revenue and patient retention. It is financially complex because standard billing workflows are not designed for it.

How should a $500-per-month membership that includes two clinical visits, unlimited messaging with a provider, and medication management be recognized? Is the entire amount recognized at the start of the month? Allocated across service delivery dates? Deferred and recognized as services are delivered? Different payers, different program structures, and different state regulations produce different answers — and accounting systems that cannot handle configurable revenue recognition rules force the finance team to manage this in spreadsheets outside the ERP.

The subscription model adds another layer:

Weight management programs that sell subscriptions — whether monthly or quarterly — carry deferred revenue obligations that need to be recognized as services are delivered. If a patient prepays for a quarterly program and cancels in month two, the financial system needs to track what was earned, what needs to be refunded, and what was deferred. Most entry-level accounting systems have no mechanism for this. NetSuite's revenue recognition module handles it natively.

THE INFRASTRUCTURE SOLUTION

What the financial infrastructure needs to look like for a GLP-1 program at scale

The financial infrastructure required to run a GLP-1 program profitably at scale is not dramatically different from what any scaled healthcare operator needs — but the specific configurations matter. NetSuite provides the platform. Archer Insights provides the configurations that make it work for the specific operational model of a weight management clinic or GLP-1 compounding pharmacy.

ARCHER CONFIGURATION SET FOR GLP-1 PROGRAM OPERATORS

FOR COMPOUNDING PHARMACIES

The specific financial management requirements of a compounding pharmacy running GLP-1s

Compounding pharmacies running GLP-1 programs have a financial profile that is distinct from clinical weight management programs. Revenue is predominantly cash-pay or patient-direct rather than insurance-billed. The primary inventory challenge is API (active pharmaceutical ingredient) procurement, quality testing, and lot-level traceability across the compounding process. And the scale ambition — for pharmacies like Strive Pharmacy, which acquired a 275,000-square-foot manufacturing facility in Alachua, Florida to expand into 503B outsourcing — requires financial infrastructure that can support both current 503A operations and future 503B regulatory requirements simultaneously.

503A operational finance

1. Patient-direct cash collection with refund and cancellation tracking across a large patient volume
2. API procurement tracking with lot-level quality documentation linked to the financial record
3. Compound-level COGS calculation including API cost, compounding labor, testing fees, and dispensing overhead
4. Multi-location consolidation across pharmacy sites with standardized controls at every location

503B readiness requirements

1. GMP-aligned financial controls with system-enforced approval authority — a 503B outsourcing facility must demonstrate documented financial controls to FDA
2. Audit-ready documentation of every financial transaction, approval chain, and vendor payment accessible without manual preparation
3. Quality cost tracking: internal QC, third-party analytical testing, and stability testing allocated at the lot level
4. SOX-style segregation of duties enforced by the system for companies with investor or lender oversight requirements

The 503B moment for GLP-1 compounding pharmacies:

The pharmacies that build 503B-ready financial infrastructure now — before the FDA requires it in the context of a specific enforcement action or inspection — will have a significant competitive advantage over those that scramble to build it under pressure. Archer has built this infrastructure for compounding pharmacy networks at the 503A-to-503B transition point and knows what regulators look for.

MARGIN MATHEMATICS

Why the financial infrastructure is a margin question, not a systems question

The business case for investing in proper financial infrastructure for a GLP-1 program is not primarily about operational efficiency. It is about margin protection. Here is the math that makes this concrete:

Financial leak | What it costs without proper infrastructure

GLP-1 billing denials at 11.8% average

For a clinic billing $3M annually in GLP-1-related services, a 9% gap between current denial rate and best-in-class represents $270K in recoverable revenue being left on the table annually

Inventory write-offs from expiration

At a compounding pharmacy dispensing $500K monthly in GLP-1s, even a 2% expiration or waste rate represents $120K annually in untracked cost that suppresses reported margin

Revenue recognition timing errors

Subscription programs with deferred revenue components that are recognized incorrectly overstate reported revenue in good months and understate it in bad ones — masking the true financial trajectory

Manual consolidation labor

A 10-location clinic group spending two weeks of senior finance time on close consolidation every month is absorbing 24 weeks per year of irreplaceable finance capacity on data assembly rather than analysis

Denied claims past timely filing

Claims that age past the timely filing window become permanent write-offs. At 40%+ of providers waiting 2+ months for reimbursement, the exposure compounds quickly without real-time denial visibility

CLOSING

The GLP-1 market will keep growing. The financial infrastructure question does not resolve itself.

The operators who built the right financial infrastructure during the GLP-1 market's first doubling will be the ones who can scale through its next phase without re-platforming in the middle of growth. The ones who manage a 10-location clinic group on QuickBooks for another two years will face the same decision at 20 locations that they should have made at 5 — but with more historical data to migrate, more complexity to configure, and a track record of financial reporting that is harder to trust.

Archer Insights has worked with compounding pharmacy networks and specialty pharmacy operators through exactly this inflection point. The GLP-1 financial management problem is solvable. The infrastructure described in this whitepaper is not aspirational — it is operational in organizations that chose to build it when the market was growing rather than after it plateaued.

Archer Insights is a five-time consecutive NetSuite Alliance Partner Spotlight Award winner (2022 through 2026), recognized for its work in the Life Sciences and Healthcare sector. Archer has served compounding pharmacies, specialty pharmacy networks, and weight management clinic operators as clients.

Call to Action

If you are running a GLP-1 weight management program or compounding pharmacy and your financial infrastructure has not kept pace with your growth, Archer can show you what the right foundation looks like.

archerinsights.com | Schedule a conversation with our healthcare team